公開中のRFP

GHIT Fund RFP Screening Platform 2024-001

The GHIT Fund established a Drug Discovery Screening Platform in early 2013 to facilitate the screening of compound libraries for identification of novel compounds for malaria, tuberculosis, Chagas disease and leishmaniasis. The goal is to leverage the active screening programs of established Product Development Partnerships (PDPs) and the relevant compound libraries from Japanese companies or academic institutions.

 

The expectation is that the Japanese entity will provide its relevant compound libraries to their PDP partner, who will then conduct screening with support from their established screening organization network. The GHIT Fund will reimburse for screening project costs.

 

Following the COVID-19 pandemic, the GHIT Fund has expanded its disease scope by adding selected Emerging and Re-Emerging Infectious Diseases for the Screening Platform. For more information, please refer to the RFP and Application Document.

 

Possible collaborations should include one of the following three leading drug development PDPs: Medicines for Malaria Venture (MMV), Drugs for Neglected Diseases initiative (DNDi), and TB Alliance.

 

GHIT Fund Management Team will contact interested parties to discuss the process of creating partnerships as well as funding.

RFP and Application Document

GHIT RFP Screening Platform 2024-001 Contact Form

Key RFP Milestone Dates

RFP Release	January 12, 2024
Application Document	Submission deadline: 10:00 am (JST) on July 5, 2024 Submit  GHIT RFP Screening Platform 2024-001  and Budget Sheet to RFPResponse@ghitfund.org Email Subject Line: Potential Screening Platform 2024-001
Q&A (RFP related questions)	Questions specific to this Screening Platform can only be answered with the submission of the "GHIT RFP Screening Platform 2024-001 Contact Form"
Notification of Results	To be announced to awarded applicants